Oral cholecystography repeated at six-month intervals is the standard method for determining reduction In future complete dissolution of gall stones should be reported only if both oral cholecystography and ultrasonographic studies give negative results and the progress of patients receiving post-dissolution maintenance treatment is monitored by ultrasonography rather than serialoral cholecystography.
Introduction
Both chenodeoxycholic acid' and ursodeoxycholic acid2 lower the cholesterol saturation of bile. Cholesterol-rich radiotranslucent gall stones exposed to such bile may gradually get smaller and even dissolve completely.1 2Since the first reports in 1972'3 4dissolution treatment has relied on oral cholecystography to show the disappearance of previously confirmed gall stones, indicating complete success.5 6 The extent to which treatment must reduce the diameter, volume, and number of gall stones to qualif, as a partial success varies from one series to another. 5 When cholelitholytic treatment is stopped the bile rapidly becomes resaturated with cholesterol. Stones are particularly likely to reform if any particulate matter is left in the gall bladder, since this may act as a seeding or nucleating agent.8 Hence patients should continue with full-dose cholelitholytic treatment for three months after the oral cholecystogram has failed to detect any remaining stones,9 since once these are reduced to less than 2 mm diameter they are below the resolution of the radiographic technique. 9 An oral cholecystogram repeated three months after the first occasionally detects stones missed on the first occasion.5 The recent National Co-operative Gallstone Study would accept gall-stone dissolution as truly complete only when both post-treatment oral cholecystograms were negative.5 The Guy's Hospital group,10 using similarly rigid criteria to define complete dissolution of gall stones, found that when treatment was withdrawn gall stones recurred in over half of the patients within two years. The British Gall-stone Study Group Post-dissolution Trial is aiming to determine (a) the timing and frequency of recurrence in patients whose stones have been dissolved medically and (b) which form of treatment will most effectively prevent recurrence. Similar studies are in progress in the USA. 5 Since ultrasound was first used to detect gall stones in 1972, refinements in instrumentation, diagnostic criteria, and scanning technique have increased the detection rate for cholelithiasis to over 95%O.1 12 If gall stones are often not detected by oral cholecystography but are by ultrasonography in patients treated medically,13 then (a) complete success is being diagnosed when tiny stones are still present; (b) treatment is being stopped too early as a result; and (c) many so-called recurrences in the post-dissolution period may simply be persistent stones which have regrown to a size at which they are once more detectable by oral cholecystography. We have therefore used ultrasonography to determine whether incomplete dissolution occurs often enough with a negative oral cholecystogram to be an important clinical problem.
Patients and methods *At this hospital patients with gall stones have been treated medically for almost five years with either chenodeoxycholic acid or the proprietary choleretic Rowachol (Rowa Ltd, Bantry, Eire) alone14 or in combination."5 Until 1980 dissolution was taken as complete if two adequate oral cholecystograms (3 g sodium ipodate at 2100 the evening before, plus 3 g calcium ipodate at 0900 on the morning of the examination) performed three months apart failed to detect stones in the gall bladder. During 1981 we used ultrasonography (Diasonograph 4200B scanner with real-time sector scanner attachment) at the same time or within a few days of the second oral cholecystogram. The gall bladder was examined longitudinally and transversely by ultrasound with the patient supine, supine with the right side raised, and in the same positions after the patient had lain prone for a short time. Occasionally we had to scan between the ribs to obtain an adequate view. The criteria for diagnosing gall stones by ultrasonography were: an echogenic focus within the gall bladder; posterior acoustic shadowing; and dependent movement of the echogenic focus with gravity. '2 During the year 14 patients with gall stones satisfied the oral cholecystographic criteria for complete dissolution, and all were also examined by ultrasonography (see table; group 1). We also recalled 11 patients whose gall stones had been completely dissolved before routine ultrasonography became available (see table; group 2). One of these had subsequently had a cholecystectomy because her gall stones had reformed and the gall bladder had become radiologically non-functioning. The remaining 10 patients, whose stones had all completely dissolved according to radiological evidence between six and 30 months before the study, agreed to undergo further oral cholecystography and abdominal ultrasonography. All 10 patients were taking a single Rowachol capsule at night to prevent reformation of gall stones. Two had had at least one recent attack of abdominal pain suggesting biliary colic; the other eight had no symptoms.
Results
Gall-bladder ultrasound showed definite evidence of at least one small stone in the gall bladder of six of the 14 patients who had had negative oral cholecystograms during the year ( 
Discussion
These results clearly confirm the value of cholecystosonography in detecting small gall stones which are missed on oral cholecystography."2 13 At present a negative oral cholecystogram is taken as evidence of complete dissolution in all reports on treatment with chenodeoxycholic acid and ursodeoxycholic acid,5 6 and cholecystography is used to monitor recurrence of gall stones0l both without treatment and during various different forms of post-dissolution maintenance treatment; hence the implications of our study are far reaching.
At the time of our study the Canadian Co-operative Gallstone Study16 reported on 13 patients treated with chenodeoxycholic acid who had achieved complete dissolution as defined by two consecutive negative oral cholecystograms at least one month apart; 6 (460%") had small stones still detectable by ultrasonography, which was almost identical with the proportion (4300) in our series. Probably in neither series had these patients had true complete dissolution, since the false-positive rate for cholecystosonography is 1 % or less.'7 Complete dissolution of gall stones on cholecystography may thus be apparent rather than real. '6 Had we not used ultrasonography as well as oral cholecystography all 14 of our patients in group 1 would have been reported as having had complete dissolution and have either stopped treatment or started some form of maintenance treatment to prevent recurrence. In fact, six of them still had stones detectable by ultrasonography. For the 11 patients who had previously apparently had complete dissolution by cholecystographic criteria our recurrence rate would have been 18%/ (two cases), which is low compared with others.'0 When ultrasonography was used seven out of 10 had gall stones. Our pilot post-dissolution maintenance study using one Rowachol capsule at night was totally invalidated because it was impossible to know how many of our patients with recurrences had ever really achieved true complete dissolution before entry to the trial. Unless ultrasonography as well as oral cholecystographic criteria are used to define true complete dissolution, postdissolution maintenance studies5 are of limited value.
The 
